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Outcomes in rheumatoid arthritis (RA) are the result of
disease activity operating over time (Table 1). In general,
the higher the level of disease activity, the more rapidly the
adverse outcomes will occur and, often, the more severe
the outcomes will be. All disease-modifying antirheumatic
drug therapy has as its goal the reduction or elimination of
disease activity and, consequently, the reduction or elimi-
nation of adverse outcomes.
Outcomes are discrete or binary events. Work disability is
such an event, as is reaching a certain level of Health
Assessment Questionnaire (HAQ) [1,2] impairment or
having an average HAQ score of 2 for a period of 1 year.
Although events are binary (0 or 1), they can be thought of
as part of an underlying, unobserved continuum. For
example, a patient can be increasingly work impaired until
the point when the patient can no longer work and
becomes work-disabled. At that point, the outcome
changes from 0 to 1.
Outcomes are also events that are associated with and
defined by duration of illness. For example, the proportion of
patients work-disabled at 10 years is a meaningful descrip-
tion, but the proportion of patients work-disabled without a
duration designator is meaningless and cannot be inter-
preted. In addition to requiring time as part of the definition
of outcome, outcome implies a sense of permanency. Out-
comes are irreversible (mortality, joint replacement) or are at
least very difficult to reverse (work disability). For functional
disability to truly be an outcome measure, it must be present
for a sustained period at a defined level.
Outcomes can be further separated as to whether they
are disease outcomes or patient outcomes. Although
these groupings may overlap, patient outcomes refer to
those outcomes that have meaning to the patient. For
example, the level of functional disability or the ability to
work are important patient outcomes, but the number of
erosions or the level of interleukin-6 are not.
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Abstract
Although functional outcome is frequently discussed and written about, it is often not clear what
functional outcome is and how it can be measured. This paper introduces the concept of latent and
observed measures of functional disability, and distinguishes between disability as a process measure
and disability as an outcome measure. Using the Health Assessment Questionnaire as the main
functional outcome measure in rheumatoid arthritis, we propose and discuss several methods for
determining disability, and describe the implications of altering the disability course.
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Outcomes, like variables, can be observed or latent. An
observed variable can be measured directly, such as age,
sex, or HAQ score. An observed outcome refers to events
like work disability, death, the number of erosions, or the
level of HAQ disability. Variables can also be unobserved
or latent, in which case they represent the underlying con-
struct or continuum that was mentioned earlier.
Latent (unobserved) variables cannot be directly mea-
sured. An example of a latent variable is happiness. Exam-
ples of latent outcomes in rheumatology are structural
damage and disablement. Although we can measure
aspects of structural damage (e.g. the presence of ero-
sions), we cannot measure the full spectrum of structural
damage because it includes abnormalities to tendons, lig-
aments, and muscles throughout the body. Similarly, dis-
ablement or disability refers to the full range of human
activities. Latent variables are important because they are
what we really want to understand but can only approach
approximately with observed variables like erosion scores
or HAQ scores. Figure 1, a model of disease activity and
outcome, illustrates these issues. Observed variables are
enclosed in rectangles, and latent variables in rounded
rectangles or ovals. In this illustration, dysfunction stands
for the unobserved outcome of functional status.
In many instances in rheumatology, we are forced to
accept the variables we can observe rather than the
underlying concepts we wish to measure. We do not have
good measures for the latent variable functional ability, so
we are forced to accept surrogates like HAQ score or
functional scores from the Medical Outcomes Study Short
Form 36 [3,4] or Arthritis Impact Measurement Scales [5].
When we accept surrogates, we introduce substantial
error because these measures are only approximate mea-
sures of function or disability. The HAQ, for example, can
be quite abnormal in individuals with little apparent func-
tional loss, and can be normal in individuals with substan-
tial and obvious dysfunction [2]. Because of the problems
in ascertaining a latent outcome, researchers often prefer-
entially measure observed outcomes such as work disabil-
ity [6–10], joint replacement surgery [11], income [12], or
death [13–16]. Yet these outcomes also have their prob-
lems because they often take too long to occur, because
they may not apply to all patients, and because they do
not touch on the day-to-day substance of RA.
Another very common approach to outcome measurement
is to use observed variables as surrogates. For functional
disability, the central outcome in RA, the HAQ becomes
Table 1
Functional outcome in rheumatoid arthritis
Is a dichotomous or binary event that can be thought of as 
representing an underlying continuum
Is defined by a time variable
Is both a patient outcome and a disease outcome
May be defined by an observed or latent variable
Can be identified using area under the curve methods
Can be identified using the sustained level method
Figure 1
A partial causal model of disease activity and outcome in rheumatoid arthritis. Rectangles represent observed variables, and ovals and rounded
rectangles represent latent (unobserved) variables. ESR/CRP, erythrocyte sedimentation rate/C-reactive protein; HAQ, Health Assessment
Questionnaire; SF-36, Medical Outcomes Study Short Form 36; QOL, quality of life; JT, joint.S13
the key functional surrogate variable. Although we have
spoken of the HAQ as the central outcome variable in RA,
it is really a dual-purpose variable, one purpose represent-
ing the short-term result of the inflammatory process of the
illness, as shown in Figure 1. Its usefulness in clinical trials
occurs because of its primary role as a measure of the
inflammatory process. It is not surprising, then, that its
second purpose can be a predictor of outcome (Fig. 2). In
fact, of all clinical variables, the HAQ is the best predictor
of outcomes such as mortality, work disability, joint
replacement, and economic loss.
For the HAQ to be considered as an outcome measure
rather than a process measure, it must be representative of
sustained impairment. But it is not easy to ascertain sus-
tained impairment. Sustained impairment implies regular
longitudinal observation, the first problem. A second
problem is that HAQ values are not well conditioned and
smooth, but tend to jump around. This has been the
subject of a number of recent papers [2,17,18], and is illus-
trated in Figures 3 and 4 (inset), where HAQ values may
vary significantly from observation to observation.
A number of approaches may be used to better define
HAQ scores, including smoothing and summarizing or
condensing. One method to better define HAQ scores
involves measuring the area under the curve (AUC) of
HAQ scores (long diagonal line of Figs 3 and 4). Notice
that the irregularity of the HAQ scores (bottom of Fig. 3
and inset of Fig. 4) is removed by the AUC measurement.
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Figure 2
A partial causal model of disease activity and outcome in rheumatoid arthritis that includes well-defined outcomes. Rectangles represent well-
defined outcomes, and ovals represent latent (unobserved) variables. The figure demonstrates the multivariate nature of outcome and the central
role of disability in rheumatoid arthritis.
Figure 3
The course of a single RA patient over 13 years of illness. Circles
represent HAQ scores. Note the wide-ranging variability of the HAQ
scores. Although it is difficult to give meaning to these HAQ scores or
analyze them, the AUC (triangles) provides smoothing that allows
further analysis. The AUC represents the total burden of RA over time,
and can be used to define functional disability as an outcome. See text
for details. RA, rheumatoid arthritis; HAQ, Health Assessment
Questionnaire; AUC, area under the curve.S14
The AUC is a measurement of the sustained burden of
functional loss on the individual. To use it as an outcome
measure, a cut-off value must be chosen. For example, we
might decide that a patient with 10 AUC units in 10 years
or 8 AUC units in 7 years has sustained clinically impor-
tant functional impairment.
One limitation of this method occurs when we are dealing
with left censored data, as is often the case in rheumatol-
ogy. In such an instance, we may choose to use as our mea-
suring period (time variable) the time the patient is under our
observation. We can alternatively choose to impute the
AUC values before the patient came under our observation,
perhaps using the average observed HAQ score. To do
this, however, introduces additional error that may or may
not be acceptable depending on the uses of the data.
Another method of determining outcome with the HAQ is
to require that a certain value of the HAQ be sustained for
a defined time period. In Figure 4 (inset), the horizontal
bidirectional arrow indicates a sustained period of HAQ
disability defined by a value of at least 2 for at least
2 years.
The investigator frequently does not have longitudinal
data. Is it correct to take a single value or a few values and
infer that they represent HAQ outcome? Given the vari-
ability of the HAQ scores in Figures 3 and 4, using a
single measure will lead to an imprecise and inefficient
measure of outcome. Additionally, it confounds the sepa-
rate definitions of process and outcome measures.
Inferences about functional disability
All recent disease-modifying antirheumatic drugs have
been shown to reduce HAQ disability over the duration of
their clinical trials [19–23]. Is it reasonable to infer
outcome differences based on shorter term results and
results that come from clinical trials, knowing that clinical
trials may not be representative of actual results in the
community? The best that can be said is that it is a start-
ing point, perhaps an indication of what we might expect
to see if drugs actually worked as well in practice as they
do in randomized clinical trials.
Using data from Figure 4, if the HAQ score was reduced
by 0.25 units (an amount of reduction shown in most
recent trials), then the total AUC of disability would be
reduced from 36.28 disability years to 31.76 disability
years, a reduction of 4.52 disability years. Using our defini-
tion of a HAQ score of 2 or greater for at least 2 years, dis-
ability would be postponed in this patient by 4.62 years.
Small changes in HAQ levels can thus translate into impor-
tant, clinically meaningful changes in outcome if all of the
assumptions noted in the present paper hold.
The importance of longitudinal studies is that they provide
the validation or refutation of the extrapolation of clinical
results to the full population of RA patients in the community.
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